Mid Florida Hematology and Oncology Center — Orange City, Florida

Public research footprint of Mid Florida Hematology and Oncology Center, compiled from the ClinicalTrials.gov public registry.

Registered studies

Active

Recruiting now

Completed

Stopped or withdrawn

Most-studied conditions

Non-small Cell Lung Cancer · Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung (NSCLC) · Renal Cell Carcinoma

Recently updated registry entries

NCT06772623 — Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab… (Recruiting)
NCT06077760 — A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus… (Recruiting)
NCT06717347 — A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus… (Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Mid Florida Hematology and Oncology Center?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 02, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.